Ethics · 26 Jul 2026

Qdenga dengue vaccine India

With reference to Qdenga, India's first dengue vaccine, consider the following statements:

  1. It is a tetravalent vaccine that, unlike its predecessor Dengvaxia, can be given without screening for prior dengue infection.
  2. It requires a single dose for full protection against all four dengue serotypes.
  3. Its protection is strongest against DENV-2 and weaker and more uncertain against DENV-3.

Which of the statements given above is/are correct?

A1 and 3 only
B2 only
C1 and 2 only
D1, 2 and 3
This question is based on: India's First Dengue Vaccine Is Here - But Can the Poor Actually Finish Both Doses?
Take this in full test mode → Instructions for 26 Jul 2026
About this question

Why in news

CDSCO approved Qdenga, India's first dengue vaccine, but its two-dose schedule and uneven serotype protection raise equity concerns for migrant workers and dense urban slum populations.

Why for UPSC

UPSC tests precise recall of a new vaccine's specific technical features (dosing schedule, screening requirement, serotype-specific efficacy) rather than just the headline fact of approval.

Prelims summary

Qdenga is a tetravalent dengue vaccine requiring two doses three months apart, needing no prior-infection screening, with protection strongest against DENV-2 and weaker against the rising DENV-3 strain.

On web, answers are shown once after a test — no save or reattempt. For unlimited reattempts, Hindi medium, and Mentor Observations, use the TAN App.